Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Oct. 05, 2022 9:27 AM ETABVC BioPharma, Inc. (ABVC)By: Anuron Mitra, SA News Editor
  • ABVC BioPharma (NASDAQ:ABVC) on Wednesday said it had got an approval from an Australian ethics committee for the phase 2 study plan for its vitreous substitute Vitargus.
  • The company subsequently submitted a clinical trial application to the Australian drug regulator, the

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.